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Introduction {#sec1}
============

Most somatic cells are replenished during life through differentiation of adult stem cells. It is suggested that differentiated cells of skeletal tissues, such as osteoblasts, marrow adipocytes, and chondrocytes, originate from putative skeletal stem cells, also referred to as mesenchymal stem cells, residing in bone marrow stroma ([@bib4], [@bib8], [@bib33]). Classical experiments on serial ectopic transplantations of bone marrow showed the existence of self-renewing skeletal stem cells, which can recapitulate formation of bone ossicle with hematopoiesis-supportive stroma ([@bib17], [@bib43], [@bib51]). Nevertheless, which cell lineages can be generated from bone marrow skeletal stem cells and how their differentiation is controlled still remains unclear. Genetic fate mapping studies using *Grem1-CreER*^*T*^ ([@bib54]), *LepR-Cre* ([@bib58]), and *Mx1-Cre* ([@bib34]) revealed distinct subsets of cells contributing to skeletal tissues, and notably each strategy resulted in labeling different cell types. This suggests that skeletal tissues may be generated by multiple subsets of stem and progenitor cells with distinct developmental potential, which may function in different locations and at particular stages of development ([@bib24]).

Heterogeneity within the population of bone marrow skeletal progenitors may also be reflected by cells cultured *in vitro*. Multiple studies revealed that single-cell-derived strains of bone marrow stromal cells (BMSCs) are heterogeneous in their differentiation potential using *in vitro* tests ([@bib2], [@bib29], [@bib32], [@bib42], [@bib45], [@bib58]) and transplantation assays ([@bib20], [@bib26], [@bib43], [@bib49]).

Several factors have been proposed to regulate lineage decisions of skeletal progenitors, among them canonical Wnt (wingless-type MMTV integration site family) ([@bib7], [@bib12], [@bib19]), VEGF (vascular endothelial growth factor) ([@bib11]), RUNX2 (runt-related transcription factor 2), and PPARγ (peroxisome proliferator-activated receptor γ) ([@bib25], [@bib52], [@bib22], [@bib31]). In fact, most of the pathways identified so far positively regulate differentiation of BMSCs into one lineage and inhibit the other, but this does not provide enough evidence that these factors actually determine cell fate decisions in a multipotent progenitor cell and not just play a role downstream during differentiation; hence, the key events in BMSC lineage commitment are still to be identified.

In this work, we specified different types of cultured skeletal progenitors within a BMSC population using *in vitro* and *in vivo* differentiation assays. Systematic expression profiling of clonally derived skeletal progenitors revealed transcriptional signatures for osteogenic and adipogenic lineages. Furthermore, we found that levels of transcription factors EGR1 and EGR2 are critical for lineage-specific expression and commitment of progenitors to osteo- and adipogenic fates.

Results {#sec2}
=======

Establishment of Clonal Skeletal Progenitors with Distinct Differentiation Properties {#sec2.1}
-------------------------------------------------------------------------------------

The main obstacles to *in vitro* studies of primary BMSCs are their limited proliferation and loss of differentiation capacity during passaging ([@bib13], [@bib29], [@bib45]). We took advantage of irtTA-GBD^∗^-TAg transgenic mice previously established in our group ([@bib1], [@bib41]), which harbor a system for inducible expression of SV40 large T antigen, and thus can be used for isolation and conditional immortalization of somatic cells ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). BMSCs isolated from the transgenic mice continuously proliferated upon induction of large T antigen by two ligands, dexamethasone and doxycycline (Dex/Dox). Large T antigen was deinduced 3 days after withdrawal of Dex/Dox, and concomitantly the cells ceased proliferation ([@bib1]). All experiments in our study were performed at least 3 days after removal of Dex/Dox unless otherwise stated, to exclude influence of these ligands and large T antigen expression.

We confirmed that conditionally immortalized BMSCs maintained the potential to differentiate into osteogenic, adipogenic, and chondrogenic lineages *in vitro* ([Figure 1](#fig1){ref-type="fig"}A), which was not altered after long-term passaging ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Nevertheless, the stringent criterion defining skeletal progenitors is their ability to generate bone at heterotopic sites in an *in vivo* transplantation assay ([@bib5], [@bib6]). To test this, we expanded two cell lines derived from individual mice for 8 passages and transplanted subcutaneously into SCID/beige mice in conjunction with a hydroxyapatite/tricalcium phosphate (HA/TCP) ceramic carrier. After 8 weeks, both transplanted BMSC lines established ossicles (4/4 and 3/4, [Figure 1](#fig1){ref-type="fig"}B). These data confirm that we established mouse BMSCs containing bona fide skeletal progenitors, which can be expanded *in vitro* using conditional immortalization while maintaining their differentiation properties.Figure 1Characterization of Mouse BMSC Lines and Clonally Derived Populations of Skeletal Progenitors(A) *In vitro* differentiation potential of BMSCs derived from whole bone marrow of irtTA-GBD^∗^-TAg transgenic mice to osteo-, adipo-, and chondrocytes (inset shows magnified region with characteristic lacunar structure of cartilage).(B) Formation of heterotopic bone in transplants derived from conditionally immortalized BMSC lines. Sections through the whole transplant and higher magnification; Sirius red and H&E.(C) Establishment of clonally derived skeletal progenitors and screening of their differentiation properties.(D) Transplantation assay of clonally derived skeletal progenitors; Sirius red staining of sections. Right panel: quantification of transplantations of cell lines and clones from 2 individual mice (4 transplants from each).Error bars indicate standard deviations (SDs). For sections of transplants: b, bone; ft, fibrous tissue; c, HA/TCP carrier; arrow, osteocyte; double arrow, osteoblast. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To explore the heterogeneity of BMSCs, we subjected conditionally immortalized BMSC lines to cellular cloning and then tested the clones for their differentiation capacity *in vitro* and *in vivo*. Using *in vitro* differentiation protocols, the clones were examined for their ability to produce mature osteo-, adipo-, and chondrogenic cells, "O", "A" and "C" respectively ([Figure 1](#fig1){ref-type="fig"}C). We identified tripotent clones ("OAC"), as well as clones capable of generating two lineages in all possible combinations ("OA", "OC" and "AC") and unipotent clones ("O", "A" and "C"). To confirm homogeneity of the established single-cell-derived clones, we performed the second round of cellular cloning and the resulting subclones were checked for osteogenic and adipogenic differentiation ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The chondrogenic assay was not tested in this experiment. Most subclones generated from the bipotent "OA" cells (78%--94%) inherited properties of the parental clones, indicating that these were homogeneous populations of cells capable of both types of differentiation and did not represent a mixture of unipotent cells. Also, 68%--96% of subclones derived from the "O" and "A" progenitors reproduced those potentials. These results suggested that clonally derived subpopulations of BMSCs relatively stably maintained their properties during culturing.

To test whether different types of progenitors pre-existed in the bone marrow and were not just a consequence of *in vitro* expansion, we isolated clonal cell populations from primary bone marrow colony-forming units---fibroblasts (CFU-Fs) by plating at low density, then immortalized and checked for osteo- and adipogenic potential ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Among the clones initiated by CFU-Fs established from five mice, bipotent "OA" and unipotent "O" and "A" cells were identified (29.6%, 63.0%, and 7.4%, respectively), confirming heterogeneity of skeletal progenitors in mice.

We tested osteogenic properties of chosen clonal skeletal progenitors further using a transplantation assay on HA/TCP carrier into immunocompromised mice. This method represents a rigorous assay for the osteogenic capacity of cells, with much lower frequency of adipocyte formation in the transplants ([@bib26], [@bib43], [@bib44]). Chondrogenic differentiation of postnatal skeletal progenitors is rarely observed in this test; therefore, we chose clones based on their osteogenic and adipogenic properties, independent of their chondrogenic capacity *in vitro*, and transplanted "OAC", "OC" and "A" clones derived from two mice. After 8 weeks, "OAC" and "A" cells produced grafts consisting of fibrotic tissue, and only "OC" clones formed bone, albeit with a lower efficiency than the parental line ([Figure 1](#fig1){ref-type="fig"}D). We also confirmed that the transplants contain donor cells by PCR genotyping using primers for irtTA and T antigen transgenes that marked the transplanted cells but not the host. Despite the fact that not all types of progenitors were tested, these data may indicate that the clones that possess osteogenic but not adipogenic capacity *in vitro* (such as "OC" and "O") can form bone *in vivo* and represent bona fide osteogenic progenitors. On the other hand, the cells capable of both osteo- and adipogenic differentiation *in vitro* (such as "OAC" and "OA") do not reveal the ability to generate bone *in vivo*, which is an apparent inconsistency between the two tests. Nevertheless, we maintained the names of the clones according to their *in vitro* potency, bearing in mind their *in vivo* potential. We further emphasize that our transplantation assay is not indicative for adipogenesis and chondrogenesis *in vivo*.

Expression Profiling of Clonally Derived Skeletal Progenitors {#sec2.2}
-------------------------------------------------------------

To characterize skeletal progenitors with distinct lineage commitment, we performed sequencing-based expression profiling (RNA sequencing \[RNA-seq\]) of the clonal populations. We used the following progenitor types according to their *in vitro* differentiation potential: "OAC", "OA", "OC", "AC", "O" and "A"; "C" cells were not analyzed due to the rarity of these clones ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We compared transcription profiles of the analyzed populations, but strikingly we could not identify genes exclusively expressed in each of the six cell types. Clustering analysis ([Figure 2](#fig2){ref-type="fig"}A) showed a strong resemblance between "OAC" and "OA" clones (25 differentially expressed genes \[DEGs\]), as well as "OC" and "O" (46 DEGs). "AC" and "A" also clustered together despite a higher number of DEGs (124 genes). This result showed that chondrogenic capacity did not largely affect transcriptome profile of the cells, at least in our system. Moreover, we suggest that different cell types did not show unique expression patterns because the clones were highly similar within the clusters. Therefore, we checked differential gene expression between three clusters: "**O**" (O + OC), "**OA**" (OA + OAC), and "**A**" (A + AC) ([Figure 2](#fig2){ref-type="fig"}B). We found 180 genes with higher expression in the "**O**" group and 186 genes in the "**A**" group; however, we could not identify specific genes for the cells with both potentials. Nevertheless, the "**OA**" group shared the expression of 102 upregulated genes with the "**O**" group and 62 genes with the "**A**" group. These data suggest that the clones that are bipotent *in vitro*, partially co-express osteogenic and adipogenic genes, and do not have unique identity. Therefore, we considered only the cells of "**O**" and "**A**" clusters for further experiments in our study.Figure 2Gene Expression Analysis of Clonally Derived Skeletal Progenitors with Distinct Differentiation Potential(A) RNA profiling of clonally derived skeletal progenitors. The distances between cell types were calculated as numbers of differentially expressed genes (DEGs) at p \< 0.01, as shown on the heatmap in (B). Darker blue corresponds to higher similarity between the clones.(B) Heatmap representing DEGs in the clusters of clones with osteogenic, adipogenic, and both potentials. Cells with both properties (**OA**: OAC + OA) co-expressed genes of osteo- (**O**: OC + O) and adipogenic (**A**: AC + A) cells and did not express unique genes.(C) Enrichment of gene ontology (GO) terms in osteogenic and adipogenic signatures of skeletal progenitors.(D) Representative genes of osteogenic and adipogenic signatures. Box plots show DEseq normalized expression values.In the box plots, the horizontal line indicates the median, and the box shows the 25^th^ and 75^th^ percentiles. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

We termed the set of genes upregulated in the "**O**" group compared with the "**A**" group as an "osteogenic signature" (282 genes) and the converse dataset as an "adipogenic signature" (248 genes). Functional annotation revealed that both osteogenic and adipogenic signatures were enriched for the genes involved in bone and skeletal system development, ossification, and development ([Figure 2](#fig2){ref-type="fig"}C), indicating a functional and developmental relationship between the two types of progenitors.

The transcriptional signatures that we described contained genes involved in osteo- and adipogenesis (such as *Sp7* \[*Osterix*\], *Dlx3*, *Dlx5* within the osteogenic, *Pparg* and *Cebpa* within the adipogenic signature), among others ([Figure 2](#fig2){ref-type="fig"}D). We verified expression of selected DEGs in independent clones ([Figure S2](#mmc1){ref-type="supplementary-material"}B), and confirmed differential expression in 88% of the cases (21/24 genes). On a special note, *Runx2* was expressed highly across all clones and was not among DEGs.

We tested expression of several proteins in the clones using immunostaining ([Figures 3](#fig3){ref-type="fig"}A and 3B) and western blot ([Figure 3](#fig3){ref-type="fig"}C). We observed high expression of SP7 in the "**O**" clones compared with "**A**", whereas the latter expressed higher PPARγ, C/EBPα, EGR2, and STAT1, in concordance with the expression profiling results. "**OA**" cells generally showed intermediate levels of expression of those markers between "**O**" and "**A**" cell types. Additionally, using co-staining with antibodies for SP7 and PPARγ, we observed that bipotent "**OA**" clones co-expressed osteogenic and adipogenic genes at the single-cell level ([Figure 3](#fig3){ref-type="fig"}A), and thus do not represent a mixture of cells with heterogeneous expression of osteo- or adipogenic signatures.Figure 3Validation of Differentially Expressed Markers in Skeletal Progenitors(A) Clonal progenitors (**O**, **OA**, and **A**) were checked for co-localization of osteogenic and adipogenic markers by co-staining with antibodies against SP7 (FITC, green) and PPARγ (TRITC, red). Insets show corresponding controls stained with only secondary antibodies.(B) Expression of DEGs characteristic for adipogenic lineage was validated by immunostaining in progenitors with **O**, **OA**, and **A** properties.(C) Expression of DEGs in BMSC clones with distinct potential from 3 mice shown by western blot. PPARγ and C/EBPα were probed sequentially on the same membrane, as well as STAT1 and SP7. Loading was confirmed by Ponceau S staining of the blot. For PPARγ and C/EBPα, the positive controls were 293 cells overexpressing corresponding proteins (controls and samples for C/EBPα were on the same membrane; much lower exposure was needed to visualize control lane).

Signaling Pathways in Lineage Commitment of Skeletal Progenitors {#sec2.3}
----------------------------------------------------------------

To find potential regulators of osteo- and adipogenic fates of skeletal progenitors, we analyzed representative members of signaling pathways in the osteogenic and adipogenic transcriptional signatures derived from our RNA-seq analysis ([Figure 4](#fig4){ref-type="fig"}A). Osteogenic cells expressed members of canonical and non-canonical Wnt, Hedgehog (SHH), parathyroid hormone (PTH), and bone morphogenetic protein (BMP) pathways, whereas adipogenic cells produced antagonists for Wnt and BMP and had upregulated targets of interferon-γ (IFNγ). To test their role in differentiation, we treated mouse conditionally immortalized clonal progenitors with the osteogenic or adipogenic medium with or without corresponding ligands ([Figures 4](#fig4){ref-type="fig"}B and 4C), including WNT3a, WNT5a, SHH, PTHrP, BMP-2, and IFNγ. The properties of "O" clones were not altered in all the aforementioned experimental conditions. However, activation of those pathways in the "A" cells affected their differentiation capacity. In the presence of WNT3a, WNT5a, and IFNγ, the cells demonstrated extensive mineralization in osteogenic conditions *in vitro*. A mild osteogenic effect was also observed after treatment with SHH, PTHrP, and BMP-2. In addition, WNT3a and IFNγ prevented adipogenic differentiation, whereas the other ligands did not. Adipogenesis was also inhibited in "OA" progenitors by emulation of WNT3a (using inhibitor of GSK3b) and IFNγ (data not shown).Figure 4IFNγ and Canonical Wnt Signaling Pathways Stimulate Osteogenic and Inhibit Adipogenic Differentiation of Skeletal Progenitors(A) Enrichment of osteo- and adipogenic transcriptional signatures for members of signaling pathways according to the RNA profiling.(B) A set of signaling molecules was tested for the effect on the osteogenic and adipogenic induction of the "O" (top) and "A" (bottom) mouse BMSC clones.(C) Dose dependence of the effect of signaling molecules on the differentiation properties of mouse clonal skeletal progenitors. Osteogenesis was quantified by elution of Alizarin Red dye and measurement of OD~490~, and adipogenesis was assessed by counting the proportion of adipocytes.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To exclude the influence of immortalization, we verified our observations using primary human BMSCs. As expected, human BMSCs could differentiate to osteogenic lineage, with or without adding WNT3a, WNT5a, SHH, PTHrP, BMP-2, and IFNγ. Yet their capacity for adipogenesis was strongly inhibited by WNT3a and IFNγ in dose-dependent manner ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Next, we established clones initiated by CFU-Fs and identified bipotent "OA" and unipotent "O" and "A" clones, confirming heterogeneity of stromal cells in human bone marrow. We showed that "A" clones could mineralize in the presence of IFNγ, which also blocked adipogenesis in those cells ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

Together, these data revealed that specific signals can induce mineralization of adipogenic progenitors at least *in vitro*, and thus potentially can dictate osteogenic fate of skeletal progenitors. Since canonical Wnt and IFNγ pathways exhibited dual effects, we ranked them as primary candidates in regulating osteogenic and adipogenic commitment. Furthermore, we decided to focus on the IFNγ pathway as it is less studied for its effects on lineage commitment of BMSCs and may reveal novel regulators of their cell fate.

EGR1 and EGR2 Control Identity of Osteo- and Adipogenic Skeletal Progenitors {#sec2.4}
----------------------------------------------------------------------------

To reveal the mechanism controlling osteogenic versus adipogenic commitment of skeletal progenitors, we performed expression profiling by RNA-seq of "O" and "A" progenitors, and the same "A" clones treated with IFNγ for 3 days ([Figures 5](#fig5){ref-type="fig"}A and 5B). IFNγ treatment of "A" cells resulted in upregulation of 626 genes and downregulation of 302 genes (p \< 0.05, fold change \>2). "O" clones had higher expression of 607 genes and lower levels of 1,153 genes compared with "A" cells. We identified 32 genes characteristic of "O" clones that could be induced in "A" cells by IFNγ ([Figure 5](#fig5){ref-type="fig"}C, upper panel), however we did not identify transcription factors among them. Next we looked at the converse datasets, and found 59 genes that were downregulated in "O" clones and inhibited by IFNγ in the "A" cells ([Figure 5](#fig5){ref-type="fig"}C, lower panel), including seven transcription factors. Remarkably, four of them belonged to the group of early response genes (*Egr1*, *Fos*, *Egr2*, *Fosb*). *Egr1* was among the top DEGs; therefore, we chose EGR1 and closely related EGR2 transcription factors for further analysis ([Figure 5](#fig5){ref-type="fig"}D).Figure 5Gene Expression in "A" Progenitors Treated with IFNγ(A) Expression of genes was analyzed in "O" clones (O4, O5, O6), "A" clones (A4, A5, and A6), and the same "A" clones treated with IFNγ for 3 days by RNA-seq. Heatmap of sample correlations based on Euclidean distances; dark blue corresponds to higher similarity.(B) Upregulation of known IFNγ-regulated genes in the clones with "A" properties upon treatment with IFNγ.(C) Analysis of RNA-seq results for differential expression of genes (p \< 0.05). The lists of overlapping DEGs were characterized for enrichment of GO terms and checked for the presence of transcription factors.(D) Comparison of *Egr1* and *Egr2* expression in clones analyzed by RNA-seq for three independent clones.

We confirmed that *Egr1* and *Egr2* were reproducibly downregulated in "A" cells in the presence of IFNγ in independent experiments ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). We performed reporter assays using luciferase gene placed under control of 3-kb upstream sequences of *Egr1* and *Egr2* genes. Luciferase signal was reduced in the presence of IFNγ in a dose-dependent manner ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D), which confirmed that downregulation of both genes occurred at the transcriptional level. Furthermore, we found enrichment of EGR1 and EGR2 in the promoters of genes for proteins involved in osteogenic and adipogenic differentiation, such as *Sp7*, *Dlx3*, *Dlx5*, *Pparg*, *Cebpa*, *Fabp4*, and *Plin4*, using chromatin immunoprecipitation (ChIP) assays ([Figure 6](#fig6){ref-type="fig"}A), suggesting that EGR1 and EGR2 can potentially regulate transcriptional programs and differentiation potency in skeletal progenitors.Figure 6EGR1 and EGR2 Control Identity of Skeletal Progenitors(A) Presence of EGR1 and EGR2 at putative binding sites in the promoter regions of known osteogenic and adipogenic regulators was tested by ChIP-qPCR in "A" clone. Percentage from input for mock was in most cases negligible; the signal in the control region in intergenic space of chromosome 9 and *Cebpa* promoter distant from binding sites (shown in red) was very low compared to the putative sites. Error bars indicate the SD of technical replicates of qPCR reactions.(B) Genetic knockdown of *Egr1* and *Egr2* was done using two independent shRNA-encoding constructs for each gene in "A" clone; expression was tested by qRT-PCR relative to the scrambled control. Error bars indicate the SD of technical replicates of qPCR reactions.(C) Gene expression analysis in the cells with *Egr1* and *Egr2* knockdown as shown by qRT-PCR relative to scrambled control. Error bars indicate the SD of technical replicates of qPCR reactions.(D) The cells with *Egr1* and *Egr2* knockdowns were tested for AP expression, osteogenic (Alizarin Red staining), and adipogenic differentiation (Oil Red O staining). Quantification: AP by counting proportion of stained cells (total number of counted cells is indicated), osteogenesis by elution of bound Alizarin Red and measurement of OD~490~, adipogenesis by counting proportion of adipocytes. Error bars indicate the SD of technical replicates.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To test the role of EGR1 and EGR2 in regulation of differentiation potency in skeletal progenitors, we performed genetic knockdown in "A" progenitors using retroviral transduction ([Figure 6](#fig6){ref-type="fig"}B). Knockdown of *Egr1* did not affect levels of osteogenic markers, such as *Alpl*, *Sp7*, *Dlx3*, and *Dlx5*, whereas adipogenic genes were significantly downregulated (*Pparg* ∼10-fold, *Cebpa* ∼5-fold to undetectable level, *Plin4* ∼10- to 20-fold, *Fabp4* ∼2-fold to undetectable) ([Figure 6](#fig6){ref-type="fig"}C). On the other hand, *Egr2* knockdown greatly upregulated osteogenic signature genes (*Alpl* ∼6- to 10-fold, *Sp7* ∼10-fold, *Dlx3* ∼3- to 5-fold, *Dlx5* ∼1.5- to 2.5-fold), while the genes associated with the adipogenic signature were not markedly changed.

Furthermore, downregulation of *Egr1* inhibited the adipogenic capacity of "A" cells ([Figure 6](#fig6){ref-type="fig"}D). The cells with *Egr2* knockdown gained osteogenic capacity and showed elevated level of alkaline phosphatase (AP), which is indicative of osteogenic propensity and could not produce adipocytes in differentiation conditions. The results of knockdown experiments were reproduced in two independent experiments and using three "A" clones.

Taken together, our data suggest that EGR1 is required for expression of the adipogenic genes, whereas downregulation of EGR2 can reactivate the osteogenic transcriptional program in adipogenic cells. Furthermore, reduction of EGR2 level is sufficient to confer osteogenic properties to adipogenic progenitors. Thus, EGR1 and EGR2 control lineage-specific gene expression and identity of skeletal progenitors.

Discussion {#sec3}
==========

Heterogeneity of BMSCs {#sec3.1}
----------------------

Skeletal stem cells (also referred to as mesenchymal stem cells) residing in bone marrow stroma are postulated to serve as common precursors for cartilage, bone, hematopoiesis-supportive stroma, and marrow adipocytes. This broad spectrum of lineages generated by skeletal stem cells has been suggested from developmental relations between those lineages, numerous *in vitro* differentiation studies ([@bib28], [@bib36], [@bib37]), and analysis of heterotopic transplants of BMSC populations ([@bib16]) isolated from adult bone marrow. Despite this model being widely accepted, so far to our knowledge the existence of a single progenitor contributing to bone, adipocytes, and chondrocytes has not been shown *in vivo* in adult mice by stringent assays such as lineage tracing or single-cell engraftment. Therefore, the questions still remain: which lineages are generated by skeletal stem cells and what factors control identity of committed progenitors?

We sought to identify which types of skeletal progenitors can be isolated from bone marrow of adult mice and how their differentiation potential can be controlled. Heterogeneity of BMSCs *in vitro* has been examined in previous studies, which described different combinations of distinct progenitor types ([@bib2], [@bib29], [@bib32], [@bib42], [@bib45], [@bib58]). Subtypes of skeletal progenitors with distinct differentiation properties have been also isolated directly from skeletal tissues ([@bib10], [@bib11]), including multipotent cells capable of generating bone, cartilage, and stroma in transplantation tests, as well as restricted bone progenitors and cartilage precursors. Nevertheless, most experiments in these works were not performed at a clonal level and the cells were isolated from fetal or neonatal tissues. In addition chondrogenic precursors were predominantly found in ear cartilage. Therefore these results are difficult to align with our clonal subpopulations of skeletal progenitors from adult bone marrow.

We found clonal progenitors with all possible seven types of differentiation potential ("OAC", "OA", "OC", "AC", "O", "A" and "C") according to *in vitro* differentiation assays, making it plausible to suggest that osteogenic, adipogenic, and chondrogenic differentiation properties can be independently combined in the clones. Our expression profiling results were consistent with this model; we identified specific transcriptional programs correlating with osteogenic and adipogenic commitment, and clones with both properties shared expression of these programs and did not show exclusive genes.

Given the findings of transcriptome analysis, we suggest that osteogenic and adipogenic signatures are not mutually exclusive and that specific types of skeletal progenitors co-express alternative lineage-specific genes. This observation contrasts with the classical view of differentiation, which is based on progression through a hierarchical system of intermediate states with specific identity. Nonetheless, the phenomenon of shared transcriptional programs has been proposed as "lineage priming" for different systems, including hematopoietic stem cells ([@bib23], [@bib27], [@bib30]) and inner cell mass of blastocyst ([@bib21], [@bib38]). These lines of evidence suggest that activation of multiple transcriptional lineage-specific signatures can be a common mechanism of early commitment of progenitors in different biological systems.

An additional question arising from our results is why the transcriptional signature for the chondrogenic lineage could not be identified from our expression profiling. We did not perform RNA-seq of "C" clones due to their rarity, and this may be the reason why this signature was not prominent in bioinformatics analysis. Yet it has been recently shown that *in vitro* chondrogenic differentiation of BMSCs can be reverted back to the undifferentiated state both *in vitro* in culture conditions for BMSCs and *in vivo* after transplantation, and thus does not represent stable commitment to chondrogenic lineage ([@bib46]). Taking into account that postnatal BMSCs have not been rigorously shown to form cartilage using *in vivo* tests such as transplantations or lineage tracing, whether bone marrow skeletal progenitors possess bona fide intrinsic chondrogenic potency still remains to be proved.

The other question is whether it is possible to predict the relationships between different subpopulations of progenitors. We performed rigorous assessment of their osteogenic potential by transplantation with HA/TCP scaffolds ([@bib26], [@bib43], [@bib44]). Despite the limited number and variety of clones assayed, our results revealed that the osteogenic clones lacking adipogenic potency ("OC") could generate bone ossicle upon transplantation, whereas all clones with adipogenic properties *in vitro* (such as "A" and "OAC") could not. One possible explanation for multipotent cells ("OAC") not being able to generate bone *in vivo* could be that these cells might require additional inductive signals from the environment to commit to osteogenic lineage, which could be present in the bone but were absent at heterotopic site of transplantation. On the other hand, these results challenge the view that clones showing multipotency *in vitro* can generate both adipo- and osteogenic lineages and are upstream of progenitors restricted to osteogenesis. It is also conceivable, although highly speculative, that osteogenic progenitors ("O") progress toward non-osteogenic state ("A"), whereas the clones combining osteogenic and adipogenic properties ("OA") represent a transitory population between those two cell types. In this case, combined expression of two signatures may reflect the process of "swapping" the programs and "OA" clones remain responsive to osteogenic cues *in vitro*, having in fact lost this potency in an *in vivo* context. This is a theoretical assumption that needs to be further explored.

Mechanisms Controlling Lineage Commitment {#sec3.2}
-----------------------------------------

Mechanisms regulating the process of differentiation in adult tissues have been intensively investigated using transgenic mice and *in vitro* cell culture systems. In contrast, knowledge of factors controlling identity of undifferentiated stem and progenitor cells is still scarce, mainly due to the inability to isolate and propagate pure populations of these cells. We characterized undifferentiated cells committed to different lineages and proposed IFNγ and WNT3a as candidates to control osteogenic and adipogenic fate.

Canonical Wnt was suggested to stimulate osteogenesis based on the phenotype in bones and BMSCs of patients with loss-of-function and gain-of-function mutations in Wnt co-receptor LRP5 ([@bib19], [@bib39]). Further experiments confirmed that canonical Wnt signaling stimulates osteogenesis while inhibiting adipogenic differentiation in cultured BMSCs ([@bib50]) and in mice ([@bib3]), which is in accord with our results.

The role of IFNγ in differentiation of skeletal progenitors is less understood, partly because IFNγ can promote osteoclast differentiation ([@bib56]), which makes it complicated to analyze the autonomous effect of IFNγ on skeletal progenitors in model organisms. Nevertheless, IFNγ was shown to enhance osteogenesis and inhibit adipogenesis in BMSCs *in vitro* and in mice after injection ([@bib15], [@bib53]). Moreover, knockout mice for *IFNγR1* receptor show impaired osteogenesis ([@bib14]), which implies a physiological role of IFNγ in differentiation of skeletal cell types. The common sources of IFNγ production are T cells, natural killer cells, and macrophages ([@bib47]). Furthermore, BMSCs may produce IFNγ in autocrine fashion ([@bib15]), although we did not detect its expression, at least in our experimental system. Therefore, in the bone marrow context, IFNγ signal may arise from interaction of skeletal progenitors with a hematopoietic compartment, or by being stimulated as an autocrine signal in response to other factors.

Expression of IFNγ targets without exogenous IFNγ in undifferentiated adipogenic clones is an interesting phenomenon, although the level of their expression was much lower than in the presence of ligand. A recent work by [@bib55] showed that undifferentiated pluripotent and tissue-specific stem cells exhibited intrinsic expression of interferon-stimulated genes (ISG) without IFNγ in the environment, and were resistant to viral infection. ISGs were downregulated during differentiation and concomitantly the cells became sensitive to viral infection. Similarly to our study, the event that induced this endogenous ISG program remained unknown. We also observed downregulation of IFNγ targets during differentiation of BMSCs (result not shown); it would be interesting to next test whether our skeletal progenitors are sensitive to viral infection.

Furthermore, our observations are congruent with the previous report that a subset of BMSCs labeled by *Mx1-Cre* induction is a stress-responsive osteogenic stem/progenitor cell population lacking detectable adipogenic capacity ([@bib34]). pIpC used for induction of *Mx1-Cre* labeling is a synthetic analog of double-stranded RNA, which induces IFNγ response in cells, including *Mx1*. Thus, it is possible that properties of *Mx1*-labeled progenitors reflect a stimulatory effect of IFNγ on osteogenic potency and suppression of adipogenic capacity that we describe. More experimental evidence, including lineage tracing and *in vivo* tracking, is required to reveal whether IFNγ-mediated modulation of cell fate specification occurs in homeostasis or regeneration.

Our transcriptome analysis and functional data from short hairpin RNA (shRNA) knockdown suggested that transcription factor EGR1 is required for expression of adipogenic regulators and adipogenesis in "A" cells, whereas EGR2 suppressed pro-osteogenic genes and osteogenic properties in "A" cells. *Egr2* knockdown also inhibited adipogenesis, indicating that EGR2 may be essential or that elevation of osteogenic regulators suppressed adipogenesis. Nevertheless, both EGR1 and EGR2 contributed to control of expression of lineage signatures in skeletal progenitors. As we found both proteins to be present in the promoters of major regulators of osteogenesis and adipogenesis (such as *Sp7*, *Dlx3*, *Dlx5*, *Pparg*, *Cebpa*), the effect on these genes can be direct. There was no major difference in EGR1 and EGR2 distribution, which is perhaps not surprising considering high similarity in their DNA binding domain ([@bib48]). Thus their distinct effects can be explained by recruitment of different interactors, which can mediate transcription activation or repression.

In concordance with our results, EGR1 and EGR2 have been shown to play a role in differentiation of skeletal tissues *in vivo*. *Egr1* knockout mice display normal osteoblastogenesis ([@bib9], [@bib40]) but increased resistance to adiposity induced by a high-fat diet ([@bib57]). On the other hand, bone marrow of *Egr2*^+*/−*^ mice contained almost 2-fold more osteogenic colony-forming units compared with the wild-type littermates, indicating increased osteogenic properties of BMSCs ([@bib18]). Together, these data indicate that EGR1 is a positive regulator of adipogenic differentiation, while EGR2 is a suppressor of osteogenesis in the skeletal progenitors *in vivo*.

In conclusion, we present here comprehensive characterization of transcriptome of distinct types of skeletal progenitors, which we believe will facilitate further investigations, including studies of their differentiation and origin. Furthermore, we found that in skeletal progenitors EGR2 suppresses osteogenic transcriptional program and differentiation propensity, whereas EGR1 maintains expression of adipogenic genes and ability to differentiate. Although many questions about the identity of skeletal progenitors remain to be answered by future studies, here we provide a previously unknown mechanism of their cell fate control.

Experimental Procedures {#sec4}
=======================

BMSC Isolation and Culture {#sec4.1}
--------------------------

BMSCs were isolated by flushing the femora and tibiae of irtTA-GBD^∗^-TAg transgenic mice. Cell expansion and differentiation were performed as described previously ([@bib41]) and in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Transplantation Assays {#sec4.2}
----------------------

The animal experiments were done under appropriate approval; the number of the authorization released by the Italian Ministry of Health is 1282/2015. 2 × 10^6^ cells were loaded onto hydroxyapatite/tricalcium phosphate (HA/TCP) particles (40 mg, 100--200 μm; Zimmer, Warsaw, IN), then subcutaneously transplanted into the backs of 6- to 15-week\--old female SCID/beige mice and analyzed after 8 weeks.

Library Preparation and Sequencing {#sec4.3}
----------------------------------

Isolation of mRNA was done using bead-based poly(dT) selection followed by chemical fragmentation and further processing for Illumina short-read sequencing (HiSeq 2000). For strand-specific sequencing, two different versions of the dUTP method ([@bib35]) were applied (for details see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

Chromatin Immunoprecipitation {#sec4.4}
-----------------------------

Protein-DNA complexes were crosslinked with 2 mM disuccinimidyl glutarate and 1% formaldehyde followed by sonication. DNA was precipitated with EGR1 or EGR2 antibody and protein G Sepharose beads, purified, and used for qPCR.

shRNA Knockdown {#sec4.5}
---------------

The gene knockdowns were done via retroviral transduction of shRNA-encoding vectors pLKO.1-puro listed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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